Thursday, 4 November 2021, 10:06 HKT/SGT

Source: Eisai
A Collaborative Cultivation Program with Dementia-related Startups

TOKYO, Nov 4, 2021 – (JCN Newswire) – Eisai Co., Ltd. announced today that it launches the “Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)”, a collaborative cultivation program jointly implemented with Digital Garage, Inc., with the aim of contributing to solving issues related to dementia and starts recruiting startups for teams to participate in the program. The program is designed to resolve various issues related to dementia with technology and science by promoting open innovation between startups and Eisai and DG, and to realize the Dementia Inclusive Society.

The program “Onlab Bio Dementia” calls for Japanese and global startups that wish to collaborate with Eisai and DG by utilizing their unique and outstanding technologies or services to solve issues related to dementia, such as brain health check and maintenance, disease awareness and testing, accurate diagnosis and confirming effectiveness of treatment (drug / non-drug), and providing care that contribute to the improvement of QOL (quality of life).

The program will help selected startups for the business growth related to dementia by combining Eisai and DG’s assets, including Eisai’s wealth of experience and knowledge in medicine creation activities and disease awareness activities in the field of dementia, DG’s business development track record and experience in the digital domain such as AI, blockchain, and digital health, and the management know- how and mentoring that DG has acquired through its efforts to provide business support to and invest in startups such as “Onlab”. In this program, Eisai and DG will implement the “Open Innovation Program” aiming to create consortium, business alliance, and investment by multiplying the technologies and services of startups with the resources of Eisai and DG, considering collaboration, and conducting demonstration experiments, etc. In addition, the “Accelerator Program” will provide mentoring by experts in various field to accelerate the business growth of startups in the seed and early stages.

Eisai has set its new medium-term business plan “EWAY Future & Beyond”, where the perspective will be shifted from that of patients to The People or each consumer. In “EWAY Future & Beyond”, with “empowering The People to realize their fullest life” as the vision, Eisai will utilize the latest digital technology such as AI and aim to remove the anxiety of “The People,” with delivering not only pharmaceutical products but also solutions to The People. For this, Eisai is progressing to build the Eisai Universal Platform (EUP) which delivers packaged solutions in addition to pharmaceutical products through synergies between the technologies of various external partners and its own R&D. In this program, which is a collaboration between Eisai and DG, Eisai will expand its contribution to “The People” based on EUP, with acquiring the opportunity for investment and collaboration in addition to building a new network with startups.

Media Inquiries:

Public Relations Department

Eisai Co., Ltd.


Topic: Press release summary

Source: Eisai

Sectors: BioTech

From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Nov 4, 2021 09:39 HKT/SGT

Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
Nov 1, 2021 08:41 HKT/SGT

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Oct 18, 2021 08:00 HKT/SGT

Eisai and Merck & Co., Inc. (Kenilworth, N.J.) Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
Sept 28, 2021 10:37 HKT/SGT

Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
Sept 27, 2021 13:50 HKT/SGT

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
Sept 14, 2021 16:46 HKT/SGT

Eisai to Join The Global Environmental Initiative “RE100”
Sept 14, 2021 11:36 HKT/SGT

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
Sept 13, 2021 15:37 HKT/SGT

AbbVie, Eisai, and EA Pharma Launch “Humira Support Tool Ordering Service for Patients”
Aug 31, 2021 08:42 HKT/SGT

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
Aug 16, 2021 09:07 HKT/SGT

Anticancer Agent “Tazverik Tablets 200mg” (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma
More news >>

Eisai and Digital Garage, Inc. Jointly Launch “Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)”
Source 1


Please enter your comment!
Please enter your name here